CRISPR Therapeutics AG (CRSP) Price to Earnings (2016 - 2026)

CRISPR Therapeutics AG has disclosed Price to Earnings across 11 years of filings, most recently posting 57.81 for Q2 2026.

• In Q2 2026, Price to Earnings fell 180.48% year-over-year to 57.81; the TTM figure through Jun 2026 stood at 10.9 (down 29.19% YoY), while the FY2025 annual figure was 8.19, up 1.01% from the prior year.
• Price to Earnings came in at 57.81 for Q2 2026 at CRISPR Therapeutics AG, down from 37.3 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 85.49 in Q4 2023 to a low of 67.22 in Q1 2023.
• Average Price to Earnings over 5 years is 32.33, with a median of 34.24 recorded in 2023.
• Year-over-year, Price to Earnings slumped 256.82% in 2022 and soared 402.31% in 2023.
• Over 5 years, Price to Earnings stood at 28.28 in 2022, then soared by 402.31% to 85.49 in 2023, then sank by 149.96% to 42.71 in 2024, then increased by 27.83% to 30.82 in 2025, then plunged by 87.54% to 57.81 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 57.81 in Q2 2026, 37.3 in Q1 2026, and 30.82 in Q4 2025.